Committee advances bill to require parity for detransition care in private plans

A Senate Business and Labor Committee on Feb. 12 voted 4–3 to favorably recommend First Substitute House Bill 258, a measure that would require private health plans that cover gender transition treatments to also cover medical care needed for detransition.

Representative Nicholeen Peck, the sponsor, told the committee the bill is narrowly focused: if a private insurer covers gender‑affirming procedures or treatment for a patient, the insurer would also be required to provide coverage for medical services related to reversing those procedures when a patient later seeks detransition care. The sponsor argued the change is one of parity so patients who later decide to reverse care are not left without codes or coverage to obtain needed treatment.

Dr. Kurt Miceli, chief medical officer for Do No Harm Action, testified in support and described harms he attributes to some gender‑affirming medical care; he told the committee "some studies suggest the rate may be as high as 30 percent" for detransition or related regret in certain studies, and urged coverage for people seeking detransition care.

Committee members pressed the sponsor on scope and potential unintended effects. Members asked whether the bill applies to ERISA/self‑funded plans and to PEHP (the state public employer plan). The sponsor and staff clarified the bill is intended to apply to commercial/private plans and does not change federal ERISA governance, but committee discussion showed ambiguity about whether PEHP‑administered plans that include local entities could be affected. Members also questioned a fiscal note listed as zero and whether including PEHP or other public employer plans would create costs for local governments; staff said enactment could increase health insurance costs for local government and educational entities whose plans cover the relevant services.

Public testimony was strongly divided. Supporters—including Phyllis Kimpel—urged the committee to vote yes so detransitioners would not be left without coverage. Opponents included transgender Utahns and their allies: Cameron Fair said a Fenway Health study found 13% of transgender people have detransitioned at some point and that the majority of those cited external factors; Charlie Fierros said the bill would "creatively discourage private insurance companies from covering gender affirming health care" and recounted that access to hormones had been lifesaving for him. Other opposing witnesses warned the bill could prompt insurers to drop or restrict gender‑affirming coverage and would exacerbate stigma and risk for transgender patients.

After closing debate, Senator McKay moved to pass the bill for substitute. The roll‑call vote passed 4–3 with Senators McKay, Musselman, Bridal and Chair Vickers voting yes and Senators Ibsen, Pitcher and Weiler voting no. The bill will proceed to the next legislative step.

The hearing recorded multiple contested factual claims about detransition rates and about whether prescriptions or hormones are used in detransition; those points were debated by witnesses and committee members. The committee did not adopt additional amendments on the floor during the hearing.